Overview

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Cetuximab to reduce the amound of circulating tumor cells in early stage NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Dutch Cancer Society
Treatments:
Cetuximab